Abstract: Low-grade cervical squamous abnormalities (lowgrade squamous intraepithelial lesions [LSIL, CIN1] ink4 staining, and 0/54 (0%) and 8/33 (24.2%) with follow-up had an HSIL outcome, respectively. Some SCJ + LSILs are more likely to both generate diagnostic disagreement and be associated with HSIL. Conversely, SCJ À LSILs generate little observer disagreement and, when followed, have a very low risk of HSIL outcome. Thus, SCJ biomarkers in conjunction with histology may segregate LSILs with very low risk of HSIL outcome and conceivably could be used as a management tool to reduce excess allocation of resources to the follow-up of these lesions.
H uman papillomavirus (HPV) has been linked to cervical cancer and its precursors from the early 1980s, 1,2 and research has uncovered >100 HPV genotypes 3 ; a successful preventive vaccine was produced in 2002. 4 Despite this, the management of women with precancerous lesions has remained inefficient, largely because of the lack of clarity regarding which precursors are most likely to progress and require excisional therapy (loop electrosurgical excision procedure [LEEP] or cone biopsy). This uncertainty has manifested largely in the classification of cervical intraepithelial neoplasia (CIN or squamous intraepithelial lesion [SIL] ). Lesions classified as CIN1 (low-grade squamous intraepithelial lesion [LSIL] ) or CIN3 (high-grade squamous intraepithelial lesion [HSIL] ) are more easily separated, justifying conservative management for the former and ablation for the latter. Lesions classified as CIN2 (HSIL) present a conundrum because of the fact that they are often treated by ablation but cannot be consistently distinguished from LSIL. The latter issue has resulted in unnecessary ablation for many lesions that confer a low risk for cancer outcome. A second problem is the fact that up to 13% of LSIL biopsies are followed by a histologic diagnosis of CIN3, [5] [6] [7] [8] [9] necessitating regular follow-up of LSIL. Thus, precursors at the lower end of the spectrum, although at low risk for malignancy during follow-up, result in considerable expense. Biomarkers such as p16 ink4 -linked to high-risk HPV infection-have been proposed to aid in this separation 10 but are diffusely positive in a significant percentage of LSILs because of the fact that the latter are often associated with carcinogenic HPVs. 11, 12 HPV DNA methylation was also suggested to be a potential biomarker for cervical cancer development. 13 However, the procedure for analyzing the methylation status using pyrosequencing assay is complex.
Most cervical cancers arise in the region of the squamocolumnar junction (SCJ). 14, 15 Recently, we discovered a discrete population of cuboidal (to low columnar) cells at the cervical SCJ that shared a unique expression profile with HSILs and cancers. 16, 17 Moreover, SCJ-specific biomarkers (keratin7, AGR2, MMP7, and GDA) also highlighted a subset of LSILs infected with high-risk HPVs and displaying an intense p16 ink4 expression. 16 The purpose of this study was to (1) survey a large population of cervical precursor lesions to determine precisely the distribution of these biomarkers, (2) identify SCJ-positive (+) and SCJ-negative (À) LSILs, and (3) compare the 2 groups with respect to their expression of p16 ink4 , proliferating index, diagnosis, and follow-up.
MATERIALS AND METHODS

Case Material and Tissue Classification
The study was approved by the institutional review board at Brigham and Women's Hospital (Boston, MA). A total of 214 formalin-fixed paraffin-embedded cervical biopsies accessioned between 2005 and 2011 were retrieved from archival material in the Women's and Perinatal Pathology Division. The original histologic diagnoses were reexamined by 2 experienced pathologists (M.R.N. and C.P.C.; the "panel") without any pathologic or clinical information and classified as LSIL or HSIL using published criteria. 18 Disagreements were resolved by a group review comprising the 2 panel pathologists. All cases were subdivided into SCJ + and SCJ À on the basis of both the staining pattern for SCJ-specific markers (positive vs. negative) (see below) and the location (the location confirmed the immunostaining profile). When an HPV-related lesion is located in the SCJ, the (pre)neoplastic epithelium displays a positive staining for all SCJ-specific markers. The majority of cases analyzed in this study were stained with all SCJ-specific antibodies. However, staining for only one of these markers is sufficient to classify a lesion as of SCJ type. To avoid misclassification of benign epithelial abnormalities, each biopsy was stained for p16 ink4 (a surrogate biomarker for carcinogenic HPV infection) and Ki67 (a proliferation marker upregulated in SILs). 12, 19, 20 For all LSIL diagnoses, pathology records of subsequent cytology (Pap smear) and follow-up diagnoses (from biopsy or excisional procedure) were reviewed when available. For each recorded follow-up diagnosis of HSIL, the pathology slides were retrieved, reviewed individually by the panel members, and the diagnosis compared with the original. For these follow-up biopsies or excisional specimens, a panel diagnosis of HSIL required an independent diagnosis of CIN2/3 by both panel members. If either member did not make an HSIL diagnosis, the follow-up biopsy was not classified as HSIL.
The purpose of this strategy was to maximize the rigor with which a follow-up diagnosis of HSIL was confirmed, given that it would imply an upgrade (HSIL) in an outcome sample.
Immunohistochemistry
Immunohistochemical analyses were performed as previously described 17, 21 Immunostaining Assessment p16 ink4 and Ki67 immunolabeling was evaluated by using a semiquantitative score based on the intensity and distribution of staining. Scoring of p16 ink4 included both nuclear and cytoplasmic staining and was graded as 0 (negative), 1 (rare dispersed positive cells), 2 (continuous over one third but no more than two thirds of the epithelial thickness), and 3 (strong and diffuse staining, uniform from basal layer to epithelial surface). Staining classified as 2 or 3 conforms to what is conventionally termed "positive" p16 ink4 staining. Scoring of Ki67 was based on nuclear staining in the upper third of the epithelium; 1, 2, 3, 4 represented samples in which positive cells were detectable in 1% to 25%, 26% to 50%, 51% to 75%, and >75%, respectively, of the designated epithelial region. Regarding AGR2, MMP7, and GDA, these SCJ-specific markers were classified as positive when intense diffuse cytoplasmic immunoreactivity of the entire cervical squamous preneoplastic epithelium was observed. Keratin7 was either expressed by the suprabasal and/or apical cell layers (positive staining) or were not expressed (negative).
DNA Isolation and HPV16/18 Detection
DNA was extracted from paraffin sections using the QIAamp FFPE tissue kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. For polymerase chain reactions, primer sequences were as follows: HPV16 forward, 5 0 -AGC TGT CAT TTA ATT GCT CAT AAC AGT A-3 0 ; HPV16 reverse, 5 0 -TGT GTC CTG AAG AAA AGC AAA GAC-3 0 ; HPV18 forward, 5 0 -CGA ACC ACA ACG TCA CAC AAT-3 0 ; HPV18 reverse, 5 0 -GCT TAC TGC TGG GAT GCA CA-3 0 . Forty cycles, including denaturation at 951C for 45 seconds, annealing for 45 seconds, and extension at 721C for 1 minute, were used for the analysis. The human b-globin control primer set (PC03-04) was used as an experimental control. Samples were run on 1.8% agarose gels containing ethidium bromide and visualized with a UV transilluminator.
Statistical Analysis
Statistical analysis was performed with the Instat 3 software (Graph-Pad Software, San Diego, CA). The Pearson w 2 test was performed to compare the significance of p16 ink4 and Ki67 expression in SCJ + and SCJ À CINs. Differences were considered statistically significant when P values were <0.05.
RESULTS
Panel Agreement and Expression of SCJ-specific Biomarkers in Cervical Preneoplastic Lesions
Reviewers agreed on a diagnosis of HSIL and LSIL in 96/97 (98.9%) and 111/117 (94.8%) cases, respectively. There was disagreement on 7 (3.3%) biopsies. These cases were resolved by a group review comprising the 2 panel pathologists. As previously shown in native cervical epithelium, neither ectocervix/transformation zone (TZ) nor endocervical epithelium reacted with the antibodies to keratin7, AGR2, GDA, and MMP7. 16 Table 1 . When located in the SCJ, preneoplastic lesions displayed a diffuse full-thickness AGR2, GDA, and MMP7 immunoreactivity. Regarding keratin7, this protein was mainly expressed in suprabasal and apical cell layers (Figs. 2, 3 Table 2 ). Figure 1 shows representative examples of preneoplastic lesions (LSIL/HSIL) analyzed in the present study. Despite the higher cellularity of the SCJ + LSILs relative to the SCJ À LSILs, the weak proliferative index compared with HSIL ( Fig. 1 and listed Table 2 summarizes the outcome data obtained from the patient records. The parameters recorded were follow-up cervical cytology, biopsies, and LEEPs, when available. Outcome was influenced by interventions (excisional procedure), thus it was not uniform between SCJ À and SCJ + LSILs. Of 78 SCJ À LSILs, follow-up information was available for 54 (69.2%) cases. The follow-up interval ranged from 6 months to 7 years. The majority of the remaining cases was obtained within a year before the study and had not yet recorded a followup sample. In all, the panel pathologists agreed on the diagnosis of LSIL. Only 2 of the 54 underwent an excisional procedure. Fifty-one percent had at least 1 followup biopsy or endocervical curettage. No HSIL diagnoses were recorded on any test. Interestingly, 6 patients had undergone an excisional procedure before the index biopsy for HSIL. Of 39 SCJ + LSILs (by the panel), 18 (46.2%) had been classified as HSIL by the original pathologist. Twenty underwent an excisional procedure, most of which had an original diagnosis of HSIL. Fifteen cases were originally diagnosed as HSIL on a follow-up conization; of the 14 (57%) reviewed by the panel pathologists, 8 were classified by both as HSIL. Of 13 cases with no excisional procedure, classified by both the panel and the original pathologist as LSIL, 7 (53.8%) had follow-up biopsy or endocervical curetting. No HSIL diagnoses (on cytology or histology) were recorded for this group. The average follow-up period for SCJ + LSILs was 28.2 months (range, 4 to 72 mo). In summary, of cases classified as LSIL by the panel, 8 of 33 (24.2%) SCJ + LSILs had a corroborated HSIL outcome, all based on an excisional procedure. In contrast, none of the 54 SCJ À LSILs (0%) was followed by an HSIL diagnosis. These differences indicate that SCJ + LSILs as a group are more heterogenous than SCJ À LSILs, and a subset is more likely to be classified as HSIL by others and thus more likely to have an HSIL outcome on a follow-up excisional procedure.
DISCUSSION
As a diagnostic entity, LSIL (or CIN1) presents 2 dilemmas to the practitioner. The first is its separation from CIN2 (HSIL), a distinction that is critical to management. An initial diagnosis of LSIL results in a 1-year follow-up period. 22, 23 In contrast, a diagnosis of CIN2, depending on the circumstances and the patient's age, could result in an excisional procedure or a closer followup interval. Excisional procedures (cone biopsy or LEEP) have been linked to a higher risk of premature delivery in subsequent pregnancies; therefore, a difference in grading between CIN1 (LSIL) and CIN2 (HSIL) can impact patient welfare. 24 A second dilemma is the follow-up risk of HSIL. Studies have estimated the risk of an HSIL outcome at 2 years or more after a diagnosis of LSIL to be Cervical Squamocolumnar Junction-specific Markers from 4% to 13%, a figure influenced somewhat by the accuracy with which the initial and follow-up diagnoses are made. [5] [6] [7] [8] [9] Moreover, studies have demonstrated that initial colposcopy only detects approximately two thirds of HSIL lesions suggesting that this rate of HSIL following LSIL could be underestimated. 25 Thus, any strategy that would clarify the risk of a given LSIL being either classified as an HSIL or being followed by HSIL would be valuable, as this distinction cannot be consistently made. 26 This study presents findings that shed light on the above conundrums with the application of markers designed empirically to determine whether the lesion in question is linked to the SCJ. The rationale for this approach is the recent discovery of SCJ-specific cells in the cervix and evidence linking them to a large proportion of HSILs, adenocarcinomas in situ, and malignancies. 16 This study uncovered a strong association between SCJspecific biomarkers and high-risk HPVs in both LSILs and HSILs and distinguished 2 forms of LSILs on the basis of these markers. We proposed that direct infection of SCJ cells by carcinogenic HPVs resulted in transdifferentiation with an outgrowth of subjacent squamous cells (so-called top-down differentiation) leading to SIL, often of high grade. 17 In contrast, infection of the ectocervical or squamous metaplastic epithelium usually resulted in LSILs. 16, 17 This dichotomy of LSILs coupled with the low frequency of HSILs on the ectocervix (and vagina) points to 2 target cell types with distinctly different risks, the SCJ cells and keratinocytes derived from either the cervical TZ or the ectocervix/vaginal epithelium. This differential susceptibility to high-grade morphology after carcinogenic HPV infection would explain the markedly different risks of vaginal and cervical HSIL and cancer. 27 Indeed, according to epidemiological studies, HPV-related lesions are 10 to 20 times more common in the cervix than in the vagina. 27 An observation of clinical significance was that certain SILs were diagnostically problematic and others were clearly not. All HSILs diagnosed by the panelists were corroborated by the original pathologist, in keeping with the fact that such lesions are not typically undercalled in practice. Panelists disagreed on 6 SCJ + LSILs. Moreover, disagreement over this group between the panel and the original pathologists was significant. Eighteen (46.2%) of 39 cases designated by the panel as SCJ + LSILs were classified as HSIL by the original pathologist. Interestingly, most of these proceeded to excision, and several were verified as HSIL by the panel. Those classified as LSIL by both the panel and the original pathologist had no HSIL outcomes. This indicates that SCJ + LSILs are heterogenous, with some behaving as LSIL, whereas others might be either underappreciated or inadequately sampled HSILs.
The more diagnostically problematic LSILs seem to be derived from a population of LSILs that usually exhibit full-thickness p16 ink4 immunostaining, positivity for SCJ biomarkers and a high frequency of HPV16. In a prior study from our group, virtually all SCJ + LSILs were carcinogenic HPV positive. 16 Regarding the percentage of p16 ink4 -positive LSILs, the rates of positivity in this study (71%) are at the high end of estimates for LSIL. 11, 12, 16 This begs the question of whether the high rate of p16 ink4 -positive LSILs in this study is because of a higher proportion of SCJ + cases in the LSIL mix or the fact that the panel classified cases as LSIL that should have been classified as HSIL.
In contrast to SCJ + LSILs, review and follow-up of LSILs lacking SCJ marker staining showed high agreement and very low risk of HSIL outcome. Not only did the panel agree on all 78 SCJ À LSILs, but the original pathologist corroborated this diagnosis in every case (This high level of agreement might seem improbable, but it should be stressed that the original diagnoses, being made in a practice situation, are not usually made in a vacuum, involving residents and, often, other consultants.) In essence, SCJ markers, by their absence, identified LSILs likely to be corroborated by multiple observers. Moreover, virtually all were followed without surgery, and none had an HSIL outcome on any diagnostic test (cytology or biopsy) during the follow-up period. Explanations include: (1) the absence of SCJ markers identifies unequivocal LSILs; and (2) infections of metaplastic or ectocervical epithelium generate an immune response that protects the SCJ from subsequent infections. Importantly, these variables suggest that variations in HSIL outcome after LSIL biopsy across different studies could be influenced by the proportion of SCJ + LSILs in the study. [5] [6] [7] [8] [9] Interestingly, 6 individuals with SCJ À LSILs had undergone a previous excisional procedure for HSIL, suggesting that subsequent infections after removal of the SCJ will be limited to residual metaplastic or ectocervical epithelium.
Regarding the potential use of SCJ markers in SIL management, 2 points should be noted. The first pertains to the use of SCJ markers to by themselves identify LSILs at higher risk for HSIL outcome. Here, it is important to note that whether the original pathologist agreed or not with the panel diagnosis of LSIL, the rate of HPV16 positivity was equivalent (52.4% vs. 55.5%). This means that the combination of SCJ + , HPV16, and strong p16 staining is still insufficient to guarantee a biopsy diagnosis of HSIL or an HSIL outcome. Because of this, we do not recommend SCJ staining (just as we do not recommend p16 immunostaining) to adjudicate the question of whether to upgrade a lesion from CIN1 to CIN2. The second point concerns the concept of using SCJ markers to-by their absence-identify LSILs conferring a very low risk for HSIL outcome. An important caveat here is that a small percentage of HSILs are SCJ À and presumably ectocervical in origin. However, the absence of HSIL outcomes in SCJ À LSILs raises the possibility that an LSIL/SCJ marker-negative combination, similar to an ASCUS/HPV-negative combination, could identify women requiring less intensive surveillance. This concept merits further study.
